ISRG pre-earnings setup: report due 2026-07-16ISRG 财报前观察：预计 2026-07-16 发布
Pre-Earnings Setup
Intuitive Surgical, Inc. (ISRG) will release its Q2 2026 earnings report on July 16, 2026, with a current market capitalization of $150.9B. Consensus analyst estimates call for $2.48 per share (EPS) and $2.824778B in total revenue, with the report scheduled just one trading day from the current date, making it a high-priority event for large-cap healthcare investors.
Earnings Relevance Context
As a leading global medical technology firm, ISRG has beaten consensus estimates in its past two quarterly reports: Q1 2026 posted actual EPS of $2.53 versus a $2.27 estimate, with revenue of $2.8662B versus a $2.762634B forecast; Q2 2026 preliminary prior report saw actual EPS of $2.50 versus a $2.12 estimate, with revenue of $2.7708B versus a $2.618749B forecast. This two-quarter streak of upside surprises has raised the baseline for market expectations ahead of the upcoming report. Recent price action includes a 5.87% daily gain on July 15, 2026, alongside July 14 analysis noting weak first-half 2026 stock performance.
Cross-Validation Signals
On July 13, 2026, CEO Rosa David J. filed a Form 4 SEC disclosure, receiving 947 shares via in-kind transfer at a price of $411.55 per share, for a total transaction value of ~$389,738, alongside multiple exempt stock transactions. Separately, 13F filings as of December 31, 2025 show 2,471 institutional holders owning 84.2% of ISRG's float, an increase of 263 institutional holders from the prior quarter, with 438 new positions and 1,408 increased positions across the institutional investor base.
Follow-up Markers
Investors should prioritize verifying actual EPS and revenue relative to consensus estimates, gross margin and free cash flow metrics, forward quarterly guidance, surgical robotics order backlog (RPO) data, and segment-specific growth trends. This signal reflects only current market expectations and publicly disclosed filing data, and does not predict actual earnings results or future stock price movement.
前置财报信息
2026年7月16日，直觉外科公司（ISRG）将发布2026年第二季度财报，当前市值1509亿美元，市场一致预期每股收益（EPS）为2.48美元，一致预期营收为28.24778亿美元，本次财报距当前仅1个交易日，是当前大型医疗科技板块的核心关注事件。
财报关注度背景
作为全球领先的医疗科技企业，ISRG过去两个季度财报均超出市场预期：2026年第一季度实际EPS为2.53美元（预期2.27美元），营收28.662亿美元（预期27.62634亿美元）；2026年4月发布的第二季度提前财报中，实际EPS达2.5美元（预期2.12美元），营收27.708亿美元（预期26.18749亿美元），连续超预期的表现推高了本次财报的市场预期基准。近期股价波动明显，7月15日当日上涨5.87%，但7月14日有分析指出其2026年上半年表现疲软。
交叉验证信号
2026年7月13日，公司首席执行官Rosa David J.提交Form 4 SEC备案，以411.55美元的价格通过实物捐赠方式获得947股公司股票，交易价值约38.97万美元，同时伴随多笔豁免性股票交易。此外，截至2025年12月31日的13F备案显示，该公司流通股84.2%由2471家机构持有，较上一季度增加263家机构，其中438家新建仓位、1408家加仓，机构持仓集中度较高。
后续关注要点
投资者需重点验证的财报数据包括：实际EPS与营收是否延续超预期趋势、毛利率与自由现金流水平、后续季度业绩指引、手术机器人业务的订单储备（RPO）及细分板块增长情况。本次信号仅反映当前市场预期与已公开的备案数据，无法预测实际财报结果或股价后续表现。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。